Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Resistance, Neoplasm | 38 | 2024 | 5336 | 2.590 |
Why?
|
Genomics | 44 | 2024 | 5926 | 2.400 |
Why?
|
Carcinoma, Renal Cell | 28 | 2024 | 3186 | 2.210 |
Why?
|
Neoplasms | 46 | 2024 | 22344 | 2.010 |
Why?
|
Kidney Neoplasms | 28 | 2024 | 4282 | 2.000 |
Why?
|
Germ-Line Mutation | 18 | 2025 | 1885 | 1.910 |
Why?
|
Immunotherapy | 27 | 2024 | 4746 | 1.750 |
Why?
|
Medical Oncology | 14 | 2024 | 2339 | 1.710 |
Why?
|
Prostatic Neoplasms | 32 | 2024 | 11094 | 1.680 |
Why?
|
Urinary Bladder Neoplasms | 15 | 2024 | 2176 | 1.650 |
Why?
|
Receptors, Androgen | 11 | 2022 | 1088 | 1.400 |
Why?
|
Melanoma | 17 | 2024 | 5695 | 1.330 |
Why?
|
Antigens, Neoplasm | 9 | 2019 | 1996 | 1.310 |
Why?
|
Mutation | 73 | 2024 | 30209 | 1.270 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 4 | 2023 | 483 | 1.150 |
Why?
|
Genomic Structural Variation | 2 | 2025 | 81 | 1.140 |
Why?
|
DNA Repair | 11 | 2021 | 2048 | 1.120 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 7 | 2023 | 105 | 1.000 |
Why?
|
High-Throughput Nucleotide Sequencing | 20 | 2022 | 3665 | 0.960 |
Why?
|
Antigen Presentation | 7 | 2021 | 1250 | 0.960 |
Why?
|
Antineoplastic Agents | 24 | 2023 | 13635 | 0.940 |
Why?
|
Proto-Oncogene Proteins B-raf | 8 | 2020 | 2054 | 0.900 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11859 | 0.890 |
Why?
|
DNA Repair-Deficiency Disorders | 2 | 2021 | 37 | 0.890 |
Why?
|
DNA Mutational Analysis | 10 | 2022 | 4112 | 0.870 |
Why?
|
Carcinoma, Transitional Cell | 5 | 2022 | 789 | 0.830 |
Why?
|
Urologic Neoplasms | 5 | 2020 | 312 | 0.820 |
Why?
|
Androgen Antagonists | 6 | 2023 | 1411 | 0.820 |
Why?
|
Tumor Microenvironment | 16 | 2024 | 3942 | 0.820 |
Why?
|
Genome, Human | 13 | 2021 | 4443 | 0.780 |
Why?
|
Bone Neoplasms | 6 | 2025 | 2559 | 0.780 |
Why?
|
Gene Expression Regulation, Neoplastic | 17 | 2024 | 8612 | 0.760 |
Why?
|
Humans | 239 | 2025 | 766117 | 0.750 |
Why?
|
Neurofibromin 1 | 2 | 2020 | 190 | 0.730 |
Why?
|
Artificial Intelligence | 8 | 2025 | 2662 | 0.730 |
Why?
|
Carcinoma | 3 | 2023 | 2313 | 0.730 |
Why?
|
Genetic Predisposition to Disease | 22 | 2025 | 18076 | 0.720 |
Why?
|
Sequence Analysis, DNA | 15 | 2021 | 4780 | 0.710 |
Why?
|
Lung Neoplasms | 14 | 2024 | 13483 | 0.700 |
Why?
|
Genetic Testing | 5 | 2024 | 3594 | 0.700 |
Why?
|
PTEN Phosphohydrolase | 6 | 2020 | 1117 | 0.660 |
Why?
|
Gene Expression Profiling | 17 | 2021 | 9527 | 0.650 |
Why?
|
Gene Fusion | 2 | 2022 | 357 | 0.640 |
Why?
|
Testicular Neoplasms | 4 | 2021 | 800 | 0.630 |
Why?
|
GTP Phosphohydrolases | 3 | 2021 | 524 | 0.620 |
Why?
|
Protein Kinase Inhibitors | 13 | 2022 | 5695 | 0.620 |
Why?
|
Skin Neoplasms | 9 | 2024 | 5836 | 0.600 |
Why?
|
Cisplatin | 6 | 2023 | 1654 | 0.600 |
Why?
|
Neoplasm Metastasis | 21 | 2024 | 4887 | 0.590 |
Why?
|
Neoadjuvant Therapy | 11 | 2024 | 2897 | 0.590 |
Why?
|
Radiation Tolerance | 2 | 2019 | 475 | 0.580 |
Why?
|
Databases, Genetic | 10 | 2021 | 1756 | 0.570 |
Why?
|
Data Display | 1 | 2018 | 174 | 0.570 |
Why?
|
Microsatellite Repeats | 2 | 2018 | 784 | 0.540 |
Why?
|
Leiomyosarcoma | 2 | 2019 | 425 | 0.530 |
Why?
|
Neuroblastoma | 1 | 2025 | 1263 | 0.530 |
Why?
|
Oncogenes | 2 | 2022 | 1232 | 0.530 |
Why?
|
Inheritance Patterns | 1 | 2018 | 345 | 0.500 |
Why?
|
Introns | 1 | 2018 | 965 | 0.500 |
Why?
|
Genome | 4 | 2020 | 1753 | 0.500 |
Why?
|
Adenocarcinoma | 8 | 2020 | 6363 | 0.500 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2022 | 2946 | 0.500 |
Why?
|
Cell Line, Tumor | 27 | 2024 | 17071 | 0.500 |
Why?
|
Male | 113 | 2025 | 363935 | 0.490 |
Why?
|
Janus Kinase 3 | 1 | 2015 | 75 | 0.480 |
Why?
|
Paternal Exposure | 1 | 2015 | 100 | 0.480 |
Why?
|
Epitopes | 2 | 2018 | 2523 | 0.470 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 161 | 0.470 |
Why?
|
Germ Cells | 7 | 2022 | 646 | 0.450 |
Why?
|
Thyroid Neoplasms | 3 | 2024 | 2354 | 0.450 |
Why?
|
Prostate-Specific Antigen | 4 | 2023 | 2463 | 0.450 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.450 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1790 | 0.440 |
Why?
|
Drug Synergism | 2 | 2016 | 1754 | 0.440 |
Why?
|
Sarcoma | 2 | 2022 | 1801 | 0.440 |
Why?
|
Immunologic Factors | 3 | 2022 | 1592 | 0.430 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 478 | 0.430 |
Why?
|
Tongue Neoplasms | 1 | 2015 | 185 | 0.420 |
Why?
|
Repressor Proteins | 2 | 2021 | 2974 | 0.420 |
Why?
|
Neoplasm Proteins | 6 | 2024 | 3594 | 0.420 |
Why?
|
TOR Serine-Threonine Kinases | 7 | 2020 | 2057 | 0.410 |
Why?
|
Nuclear Proteins | 5 | 2024 | 5791 | 0.400 |
Why?
|
Molecular Targeted Therapy | 11 | 2024 | 2824 | 0.400 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 1765 | 0.400 |
Why?
|
Urothelium | 1 | 2014 | 275 | 0.400 |
Why?
|
Cell Survival | 2 | 2021 | 5747 | 0.390 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 409 | 0.380 |
Why?
|
Urinary Bladder | 1 | 2017 | 1155 | 0.380 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5784 | 0.370 |
Why?
|
Physician-Patient Relations | 3 | 2025 | 3270 | 0.370 |
Why?
|
Phosphatidylinositol 3-Kinases | 7 | 2018 | 2877 | 0.360 |
Why?
|
Mouth Neoplasms | 2 | 2018 | 595 | 0.360 |
Why?
|
Signal Transduction | 17 | 2024 | 23605 | 0.360 |
Why?
|
Prostate | 3 | 2022 | 1758 | 0.350 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1183 | 0.350 |
Why?
|
Colorectal Neoplasms | 7 | 2021 | 6961 | 0.340 |
Why?
|
Ketones | 2 | 2021 | 183 | 0.340 |
Why?
|
Furans | 2 | 2021 | 199 | 0.340 |
Why?
|
Transcription, Genetic | 4 | 2021 | 7600 | 0.330 |
Why?
|
DNA, Neoplasm | 5 | 2018 | 1739 | 0.320 |
Why?
|
Biopsy | 7 | 2024 | 6768 | 0.320 |
Why?
|
Endogenous Retroviruses | 2 | 2022 | 111 | 0.320 |
Why?
|
CD8-Positive T-Lymphocytes | 8 | 2024 | 4649 | 0.310 |
Why?
|
Cystectomy | 3 | 2024 | 603 | 0.310 |
Why?
|
Cell Cycle Proteins | 4 | 2024 | 3436 | 0.310 |
Why?
|
Ovarian Neoplasms | 2 | 2023 | 4904 | 0.310 |
Why?
|
Middle Aged | 63 | 2024 | 223083 | 0.310 |
Why?
|
T-Lymphocytes | 8 | 2024 | 10260 | 0.310 |
Why?
|
Models, Genetic | 1 | 2018 | 3448 | 0.300 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1425 | 0.290 |
Why?
|
Treatment Refusal | 1 | 2011 | 433 | 0.290 |
Why?
|
Software | 3 | 2020 | 4463 | 0.290 |
Why?
|
Antibodies, Monoclonal | 6 | 2024 | 9237 | 0.290 |
Why?
|
Female | 75 | 2025 | 396233 | 0.290 |
Why?
|
Aged | 53 | 2024 | 171219 | 0.280 |
Why?
|
Membrane Proteins | 4 | 2021 | 7850 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5388 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4049 | 0.280 |
Why?
|
Gene Dosage | 4 | 2021 | 1213 | 0.280 |
Why?
|
Prostatectomy | 5 | 2023 | 1786 | 0.270 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2022 | 1105 | 0.270 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2024 | 303 | 0.270 |
Why?
|
Anus Neoplasms | 2 | 2024 | 336 | 0.270 |
Why?
|
Neoplasm Invasiveness | 7 | 2023 | 3602 | 0.270 |
Why?
|
Sulfonamides | 4 | 2018 | 1980 | 0.260 |
Why?
|
Phenylthiohydantoin | 4 | 2021 | 206 | 0.260 |
Why?
|
DNA Mismatch Repair | 2 | 2019 | 432 | 0.250 |
Why?
|
Melanoma, Experimental | 2 | 2020 | 555 | 0.250 |
Why?
|
Computer Simulation | 2 | 2018 | 6254 | 0.250 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2018 | 949 | 0.250 |
Why?
|
Patient Care | 1 | 2011 | 630 | 0.250 |
Why?
|
DNA Copy Number Variations | 8 | 2023 | 2045 | 0.240 |
Why?
|
Breast Neoplasms | 9 | 2024 | 21074 | 0.240 |
Why?
|
Tumor Escape | 2 | 2018 | 371 | 0.240 |
Why?
|
Cohort Studies | 17 | 2022 | 41684 | 0.240 |
Why?
|
Death | 1 | 2009 | 686 | 0.240 |
Why?
|
Neuroendocrine Tumors | 3 | 2023 | 657 | 0.230 |
Why?
|
Neoplasm Staging | 8 | 2024 | 11200 | 0.230 |
Why?
|
Genetic Heterogeneity | 5 | 2024 | 735 | 0.230 |
Why?
|
Transcription Factors | 9 | 2023 | 12130 | 0.230 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2532 | 0.230 |
Why?
|
Phthalazines | 2 | 2024 | 397 | 0.230 |
Why?
|
DNA Damage | 4 | 2022 | 2463 | 0.230 |
Why?
|
Ploidies | 1 | 2024 | 287 | 0.230 |
Why?
|
Computational Biology | 6 | 2024 | 3565 | 0.220 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 3604 | 0.220 |
Why?
|
Genome-Wide Association Study | 6 | 2022 | 12803 | 0.220 |
Why?
|
Cyclic AMP Response Element-Binding Protein A | 2 | 2022 | 21 | 0.220 |
Why?
|
Radium | 1 | 2024 | 70 | 0.220 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59515 | 0.220 |
Why?
|
Chromosome Aberrations | 2 | 2025 | 1775 | 0.220 |
Why?
|
Adult | 40 | 2025 | 223139 | 0.210 |
Why?
|
Platinum | 2 | 2022 | 219 | 0.210 |
Why?
|
Tumor Suppressor Proteins | 6 | 2024 | 2795 | 0.210 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2021 | 259 | 0.200 |
Why?
|
Allergy and Immunology | 1 | 2024 | 170 | 0.200 |
Why?
|
Nitriles | 4 | 2021 | 981 | 0.200 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2021 | 634 | 0.200 |
Why?
|
MAP Kinase Signaling System | 4 | 2018 | 1490 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 3 | 2021 | 4521 | 0.200 |
Why?
|
Benzamides | 4 | 2021 | 1376 | 0.200 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 43 | 0.200 |
Why?
|
Attitude to Health | 1 | 2011 | 2020 | 0.200 |
Why?
|
Antigen-Antibody Complex | 1 | 2024 | 508 | 0.190 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2022 | 257 | 0.190 |
Why?
|
Genes, Neoplasm | 3 | 2018 | 369 | 0.190 |
Why?
|
Stomach Neoplasms | 2 | 2023 | 1471 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 205 | 0.180 |
Why?
|
Intestinal Neoplasms | 1 | 2023 | 314 | 0.180 |
Why?
|
Alkylating Agents | 1 | 2021 | 133 | 0.180 |
Why?
|
Multiple Myeloma | 4 | 2020 | 5189 | 0.180 |
Why?
|
False Positive Reactions | 2 | 2016 | 956 | 0.180 |
Why?
|
Androgens | 3 | 2023 | 1278 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 904 | 0.180 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 116 | 0.180 |
Why?
|
Microsatellite Instability | 3 | 2020 | 726 | 0.180 |
Why?
|
Osteosarcoma | 2 | 2018 | 908 | 0.180 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2926 | 0.180 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 580 | 0.180 |
Why?
|
Disease Progression | 9 | 2024 | 13616 | 0.180 |
Why?
|
Pyrimidinones | 2 | 2020 | 384 | 0.170 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2021 | 199 | 0.170 |
Why?
|
Epigenesis, Genetic | 5 | 2024 | 3818 | 0.170 |
Why?
|
Therapies, Investigational | 1 | 2021 | 110 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 384 | 0.170 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 299 | 0.170 |
Why?
|
Sesquiterpenes | 1 | 2020 | 175 | 0.170 |
Why?
|
Myeloid Cells | 1 | 2024 | 839 | 0.170 |
Why?
|
Morpholines | 2 | 2020 | 584 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2020 | 125 | 0.160 |
Why?
|
Animals | 29 | 2024 | 168800 | 0.160 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2662 | 0.160 |
Why?
|
Carboplatin | 1 | 2022 | 787 | 0.160 |
Why?
|
Paraffin Embedding | 1 | 2020 | 302 | 0.160 |
Why?
|
Tissue Fixation | 1 | 2020 | 245 | 0.160 |
Why?
|
Muscles | 5 | 2022 | 1576 | 0.160 |
Why?
|
Cardiology | 1 | 2010 | 1696 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 323 | 0.160 |
Why?
|
Survival Analysis | 8 | 2021 | 10087 | 0.160 |
Why?
|
Gene Amplification | 2 | 2021 | 1088 | 0.160 |
Why?
|
Histone Demethylases | 2 | 2020 | 328 | 0.160 |
Why?
|
raf Kinases | 2 | 2016 | 116 | 0.160 |
Why?
|
Aminopyridines | 2 | 2020 | 576 | 0.160 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 123 | 0.160 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.160 |
Why?
|
Watchful Waiting | 1 | 2023 | 492 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 209 | 0.160 |
Why?
|
Mice | 22 | 2024 | 81839 | 0.160 |
Why?
|
Biology | 1 | 2021 | 293 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2018 | 352 | 0.150 |
Why?
|
Multifactorial Inheritance | 2 | 2024 | 1426 | 0.150 |
Why?
|
Epigenomics | 1 | 2024 | 959 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
RNA-Induced Silencing Complex | 1 | 2018 | 52 | 0.150 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2022 | 792 | 0.150 |
Why?
|
Algorithms | 4 | 2018 | 14066 | 0.150 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 176 | 0.150 |
Why?
|
Gene Library | 1 | 2021 | 1066 | 0.150 |
Why?
|
Quality Control | 1 | 2021 | 835 | 0.150 |
Why?
|
Proteome | 2 | 2021 | 1896 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2018 | 561 | 0.150 |
Why?
|
Prospective Studies | 11 | 2024 | 54812 | 0.140 |
Why?
|
Spliceosomes | 1 | 2018 | 116 | 0.140 |
Why?
|
DNA-Binding Proteins | 6 | 2022 | 9601 | 0.140 |
Why?
|
Pyrazoles | 2 | 2020 | 2031 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 2 | 2022 | 167 | 0.140 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2021 | 343 | 0.140 |
Why?
|
Epitope Mapping | 1 | 2018 | 300 | 0.140 |
Why?
|
Terminal Care | 1 | 2009 | 1769 | 0.140 |
Why?
|
Nucleotides | 1 | 2020 | 453 | 0.140 |
Why?
|
Chromatin | 3 | 2025 | 2981 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 9378 | 0.140 |
Why?
|
Immunity, Cellular | 2 | 2020 | 1557 | 0.140 |
Why?
|
Treatment Outcome | 16 | 2024 | 65219 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 50 | 0.140 |
Why?
|
Cullin Proteins | 1 | 2018 | 180 | 0.140 |
Why?
|
Electron Transport Complex I | 1 | 2018 | 150 | 0.140 |
Why?
|
Pyrimidines | 3 | 2024 | 3050 | 0.140 |
Why?
|
Students, Medical | 1 | 2010 | 1962 | 0.140 |
Why?
|
Phenotype | 6 | 2023 | 16716 | 0.140 |
Why?
|
Prognosis | 15 | 2023 | 29912 | 0.140 |
Why?
|
Adenoma, Oxyphilic | 1 | 2018 | 150 | 0.130 |
Why?
|
Liposarcoma | 1 | 2019 | 288 | 0.130 |
Why?
|
Risk Factors | 9 | 2025 | 74857 | 0.130 |
Why?
|
Bone Marrow Neoplasms | 1 | 2017 | 101 | 0.130 |
Why?
|
Receptors, Estrogen | 3 | 2021 | 2242 | 0.130 |
Why?
|
Indoles | 2 | 2015 | 1833 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2024 | 5454 | 0.130 |
Why?
|
Survival Rate | 6 | 2021 | 12827 | 0.130 |
Why?
|
Radiation Oncology | 1 | 2022 | 568 | 0.130 |
Why?
|
Quinoxalines | 1 | 2018 | 296 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 752 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2021 | 453 | 0.130 |
Why?
|
Data Mining | 1 | 2021 | 560 | 0.130 |
Why?
|
Immunity | 2 | 2019 | 1001 | 0.130 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 220 | 0.130 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 571 | 0.130 |
Why?
|
Glutathione | 1 | 2018 | 589 | 0.130 |
Why?
|
Lysine | 1 | 2020 | 994 | 0.130 |
Why?
|
Immunohistochemistry | 5 | 2020 | 11035 | 0.120 |
Why?
|
Electronic Health Records | 6 | 2023 | 4863 | 0.120 |
Why?
|
Proteins | 2 | 2021 | 5995 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3501 | 0.120 |
Why?
|
Immunologic Surveillance | 1 | 2016 | 92 | 0.120 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2015 | 330 | 0.120 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2020 | 1677 | 0.120 |
Why?
|
Medulloblastoma | 1 | 2020 | 657 | 0.120 |
Why?
|
Oximes | 2 | 2013 | 305 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1535 | 0.120 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 252 | 0.120 |
Why?
|
Oncogene Proteins | 2 | 2020 | 711 | 0.120 |
Why?
|
Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2010 | 4527 | 0.120 |
Why?
|
RNA | 3 | 2022 | 2716 | 0.120 |
Why?
|
HEK293 Cells | 2 | 2014 | 4263 | 0.120 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2019 | 632 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 1559 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1328 | 0.120 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 663 | 0.110 |
Why?
|
Deoxycytidine | 2 | 2017 | 886 | 0.110 |
Why?
|
Reproducibility of Results | 4 | 2021 | 20137 | 0.110 |
Why?
|
Mitochondria | 2 | 2018 | 3672 | 0.110 |
Why?
|
Uveal Neoplasms | 1 | 2017 | 343 | 0.110 |
Why?
|
Gene Silencing | 1 | 2020 | 1504 | 0.110 |
Why?
|
Disease Models, Animal | 5 | 2024 | 18321 | 0.110 |
Why?
|
Documentation | 1 | 2020 | 911 | 0.110 |
Why?
|
Teratoma | 1 | 2016 | 402 | 0.110 |
Why?
|
Indazoles | 3 | 2024 | 306 | 0.110 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2013 | 92 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1609 | 0.110 |
Why?
|
Androstenes | 2 | 2019 | 177 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2547 | 0.110 |
Why?
|
Mass Screening | 1 | 2009 | 5450 | 0.110 |
Why?
|
Phylogeny | 2 | 2021 | 2838 | 0.110 |
Why?
|
History, 21st Century | 1 | 2019 | 1574 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2023 | 1621 | 0.100 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2012 | 30 | 0.100 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 723 | 0.100 |
Why?
|
Comprehension | 1 | 2018 | 636 | 0.100 |
Why?
|
Aptamers, Nucleotide | 1 | 2013 | 163 | 0.100 |
Why?
|
Incidental Findings | 2 | 2016 | 698 | 0.100 |
Why?
|
Testis | 1 | 2015 | 782 | 0.100 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2013 | 705 | 0.100 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 506 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2018 | 2590 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7424 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1637 | 0.100 |
Why?
|
Mediator Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 2 | 2018 | 1068 | 0.090 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2018 | 1897 | 0.090 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15403 | 0.090 |
Why?
|
Spermatozoa | 1 | 2015 | 627 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2024 | 81565 | 0.090 |
Why?
|
Ubiquitin Thiolesterase | 3 | 2021 | 455 | 0.090 |
Why?
|
Evolution, Molecular | 2 | 2016 | 1889 | 0.090 |
Why?
|
Anecdotes as Topic | 1 | 2011 | 56 | 0.090 |
Why?
|
Mice, Inbred NOD | 3 | 2020 | 1837 | 0.090 |
Why?
|
Child, Preschool | 4 | 2025 | 42511 | 0.090 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2017 | 1362 | 0.090 |
Why?
|
Conserved Sequence | 1 | 2014 | 1159 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3546 | 0.090 |
Why?
|
Child | 7 | 2025 | 80573 | 0.090 |
Why?
|
Young Adult | 12 | 2022 | 59868 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2060 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 8038 | 0.090 |
Why?
|
Imidazoles | 2 | 2013 | 1169 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5752 | 0.090 |
Why?
|
Sex Factors | 1 | 2025 | 10614 | 0.090 |
Why?
|
Cancer Vaccines | 1 | 2018 | 1042 | 0.090 |
Why?
|
Paracentesis | 1 | 2011 | 99 | 0.090 |
Why?
|
Blood Proteins | 1 | 2016 | 1186 | 0.090 |
Why?
|
Sick Role | 1 | 2011 | 229 | 0.090 |
Why?
|
Humanism | 1 | 2011 | 84 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4853 | 0.090 |
Why?
|
Metabolomics | 1 | 2019 | 1667 | 0.080 |
Why?
|
Internship and Residency | 1 | 2010 | 5946 | 0.080 |
Why?
|
HLA Antigens | 1 | 2015 | 1338 | 0.080 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 2091 | 0.080 |
Why?
|
Lymphocytes | 1 | 2018 | 2602 | 0.080 |
Why?
|
Protein Conformation | 2 | 2014 | 3946 | 0.080 |
Why?
|
Histones | 1 | 2020 | 2591 | 0.080 |
Why?
|
Quinolines | 1 | 2015 | 769 | 0.080 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 831 | 0.080 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 385 | 0.080 |
Why?
|
Androstenols | 1 | 2009 | 25 | 0.080 |
Why?
|
Proteomics | 2 | 2021 | 3907 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2838 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9599 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3584 | 0.080 |
Why?
|
Mice, Nude | 3 | 2018 | 3610 | 0.080 |
Why?
|
Remission Induction | 1 | 2015 | 2413 | 0.080 |
Why?
|
Ketoconazole | 1 | 2009 | 95 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1120 | 0.080 |
Why?
|
Neutrophils | 2 | 2019 | 3771 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2430 | 0.080 |
Why?
|
Pedigree | 1 | 2016 | 4535 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2844 | 0.080 |
Why?
|
Research Design | 2 | 2021 | 6206 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4399 | 0.080 |
Why?
|
Sequence Analysis | 2 | 2022 | 240 | 0.070 |
Why?
|
Natural Language Processing | 3 | 2021 | 1198 | 0.070 |
Why?
|
Hormones | 2 | 2022 | 865 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4617 | 0.070 |
Why?
|
RNA, Double-Stranded | 2 | 2020 | 292 | 0.070 |
Why?
|
Genes, Tumor Suppressor | 2 | 2024 | 1060 | 0.070 |
Why?
|
Survivors | 1 | 2018 | 2375 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1541 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 702 | 0.070 |
Why?
|
Models, Molecular | 2 | 2014 | 5382 | 0.070 |
Why?
|
Quality of Life | 3 | 2024 | 13468 | 0.070 |
Why?
|
Pyridines | 2 | 2018 | 2889 | 0.070 |
Why?
|
Professional-Family Relations | 1 | 2011 | 500 | 0.070 |
Why?
|
Sequence Analysis, RNA | 3 | 2020 | 2039 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2016 | 1076 | 0.070 |
Why?
|
Genetic Variation | 3 | 2016 | 6612 | 0.070 |
Why?
|
Alleles | 1 | 2017 | 6892 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2455 | 0.070 |
Why?
|
DNA Helicases | 2 | 2023 | 852 | 0.070 |
Why?
|
Medical Informatics | 1 | 2013 | 743 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2011 | 1836 | 0.070 |
Why?
|
Receptors, Progesterone | 2 | 2021 | 1152 | 0.060 |
Why?
|
Radiography | 2 | 2014 | 6943 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26290 | 0.060 |
Why?
|
Cyclin D1 | 2 | 2018 | 449 | 0.060 |
Why?
|
Professional-Patient Relations | 1 | 2011 | 723 | 0.060 |
Why?
|
DNA Methylation | 4 | 2024 | 4425 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14645 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2014 | 1379 | 0.060 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2024 | 50 | 0.060 |
Why?
|
Pteridines | 1 | 2014 | 47 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1883 | 0.060 |
Why?
|
Europe | 2 | 2024 | 3430 | 0.060 |
Why?
|
Single-Cell Analysis | 3 | 2024 | 2536 | 0.060 |
Why?
|
Phosphoproteins | 1 | 2013 | 2445 | 0.060 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 115 | 0.060 |
Why?
|
RNA Interference | 1 | 2013 | 2828 | 0.060 |
Why?
|
Mice, SCID | 2 | 2020 | 2626 | 0.060 |
Why?
|
Decision Support Systems, Clinical | 1 | 2013 | 1177 | 0.060 |
Why?
|
Phosphorylation | 1 | 2015 | 8292 | 0.060 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1416 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5510 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2020 | 16040 | 0.060 |
Why?
|
Up-Regulation | 2 | 2023 | 4133 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2011 | 1432 | 0.050 |
Why?
|
INDEL Mutation | 2 | 2015 | 267 | 0.050 |
Why?
|
Health Surveys | 1 | 2013 | 4058 | 0.050 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2020 | 698 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4408 | 0.050 |
Why?
|
Castration | 1 | 2023 | 149 | 0.050 |
Why?
|
bcl-X Protein | 1 | 2014 | 412 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 512 | 0.050 |
Why?
|
Electric Power Supplies | 1 | 2023 | 94 | 0.050 |
Why?
|
Receptor, erbB-2 | 3 | 2020 | 2593 | 0.050 |
Why?
|
HIV Infections | 1 | 2009 | 17535 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2023 | 303 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7582 | 0.050 |
Why?
|
Chromosomal Instability | 1 | 2023 | 176 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 146 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4859 | 0.050 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 249 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 367 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8525 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2024 | 582 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 113 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 167 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 299 | 0.050 |
Why?
|
Arabs | 1 | 2023 | 190 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6840 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8882 | 0.050 |
Why?
|
Medical History Taking | 1 | 2025 | 779 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2020 | 2718 | 0.040 |
Why?
|
Apoptosis | 1 | 2016 | 9508 | 0.040 |
Why?
|
Dactinomycin | 1 | 2020 | 304 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 878 | 0.040 |
Why?
|
Random Allocation | 1 | 2014 | 2395 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 155 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4352 | 0.040 |
Why?
|
Adenosine | 1 | 2024 | 813 | 0.040 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2021 | 361 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20700 | 0.040 |
Why?
|
Histocompatibility Antigens | 1 | 2021 | 479 | 0.040 |
Why?
|
Aneuploidy | 1 | 2023 | 576 | 0.040 |
Why?
|
Societies, Medical | 2 | 2024 | 3955 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 4910 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 526 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 370 | 0.040 |
Why?
|
Kynurenine | 1 | 2019 | 142 | 0.040 |
Why?
|
Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2021 | 211 | 0.040 |
Why?
|
Databases, Protein | 1 | 2021 | 391 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6545 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2504 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 559 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 533 | 0.040 |
Why?
|
Infant | 2 | 2022 | 36427 | 0.040 |
Why?
|
Melanoma-Specific Antigens | 1 | 2018 | 73 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 109 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10380 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 591 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 354 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 937 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 329 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 370 | 0.040 |
Why?
|
Computer Graphics | 1 | 2019 | 345 | 0.040 |
Why?
|
Tablets | 1 | 2018 | 149 | 0.040 |
Why?
|
Eukaryotic Initiation Factor-1 | 1 | 2017 | 31 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 791 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 1054 | 0.040 |
Why?
|
Entropy | 1 | 2018 | 209 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 483 | 0.040 |
Why?
|
Estradiol | 1 | 2014 | 1947 | 0.040 |
Why?
|
Veterans | 1 | 2011 | 2667 | 0.030 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 246 | 0.030 |
Why?
|
DNA | 2 | 2024 | 7193 | 0.030 |
Why?
|
Gene Duplication | 1 | 2018 | 316 | 0.030 |
Why?
|
Genes, myc | 1 | 2018 | 391 | 0.030 |
Why?
|
beta Catenin | 1 | 2022 | 1047 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 5503 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2890 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2019 | 820 | 0.030 |
Why?
|
Cell Line | 2 | 2022 | 15546 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2018 | 640 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1441 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 329 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2469 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1552 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3274 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3424 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1208 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1138 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1384 | 0.030 |
Why?
|
Genes, Neurofibromatosis 2 | 1 | 2015 | 122 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2015 | 23 | 0.030 |
Why?
|
Language | 1 | 2025 | 1550 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 413 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 239 | 0.030 |
Why?
|
Fumarate Hydratase | 1 | 2015 | 55 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 2125 | 0.030 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2015 | 68 | 0.030 |
Why?
|
Genes, p16 | 1 | 2015 | 157 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2018 | 947 | 0.030 |
Why?
|
Kidney Tubules, Collecting | 1 | 2015 | 163 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 938 | 0.030 |
Why?
|
Genes, ras | 1 | 2017 | 656 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 659 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1528 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7426 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1950 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 975 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10433 | 0.030 |
Why?
|
Interferon Type I | 1 | 2018 | 568 | 0.030 |
Why?
|
National Human Genome Research Institute (U.S.) | 1 | 2013 | 22 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2015 | 9065 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.030 |
Why?
|
HeLa Cells | 1 | 2020 | 3073 | 0.030 |
Why?
|
Wnt Proteins | 1 | 2018 | 721 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2014 | 182 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1318 | 0.030 |
Why?
|
RNA, Neoplasm | 1 | 2016 | 745 | 0.030 |
Why?
|
Interferons | 1 | 2017 | 714 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2022 | 2864 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 40108 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 22341 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1762 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1157 | 0.030 |
Why?
|
United States | 4 | 2022 | 72920 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2570 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1143 | 0.030 |
Why?
|
Cell Count | 1 | 2017 | 1825 | 0.030 |
Why?
|
DNA, Mitochondrial | 1 | 2018 | 870 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1865 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 1310 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2667 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2016 | 2743 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 2016 | 931 | 0.020 |
Why?
|
Haplotypes | 1 | 2018 | 2726 | 0.020 |
Why?
|
Leukocytes | 1 | 2020 | 2030 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1363 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2425 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 789 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 562 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2136 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 8113 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2013 | 334 | 0.020 |
Why?
|
Stromal Cells | 1 | 2016 | 1332 | 0.020 |
Why?
|
Communication | 1 | 2025 | 3909 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1651 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2018 | 1996 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15827 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1349 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6102 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 792 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 1985 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3623 | 0.020 |
Why?
|
Biomedical Research | 1 | 2024 | 3458 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6506 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2630 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 2227 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2015 | 1743 | 0.020 |
Why?
|
Cell Communication | 1 | 2016 | 1660 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1241 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1641 | 0.020 |
Why?
|
NF-kappa B | 1 | 2017 | 2495 | 0.020 |
Why?
|
Protein Binding | 1 | 2021 | 9301 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39243 | 0.020 |
Why?
|
Workflow | 1 | 2013 | 859 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3202 | 0.020 |
Why?
|
Pyridones | 1 | 2013 | 817 | 0.020 |
Why?
|
Genetic Markers | 1 | 2014 | 2603 | 0.020 |
Why?
|
Bone Marrow | 1 | 2018 | 2916 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2920 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2249 | 0.020 |
Why?
|
Adolescent | 3 | 2022 | 88819 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5881 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11642 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4249 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 13028 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3238 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23717 | 0.020 |
Why?
|
Patient Preference | 1 | 2013 | 947 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9540 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8347 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 7050 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 13400 | 0.010 |
Why?
|
Base Sequence | 1 | 2016 | 12405 | 0.010 |
Why?
|
Family | 1 | 2016 | 3208 | 0.010 |
Why?
|
Liver | 1 | 2020 | 7559 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3456 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2016 | 3586 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10737 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14456 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26381 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12775 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22228 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14747 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11906 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18386 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21513 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 24276 | 0.010 |
Why?
|